Home › Compare › DVAX vs O

DVAX vs O: Dividend Comparison 2026

DVAX yields 12.90% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DVAX wins by $12.5K in total portfolio value
10 years
DVAX
DVAX
● Live price
12.90%
Share price
$15.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.8K
Annual income
$2,879.44
Full DVAX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — DVAX vs O

📍 DVAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDVAXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DVAX + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DVAX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DVAX
Annual income on $10K today (after 15% tax)
$1,096.77/yr
After 10yr DRIP, annual income (after tax)
$2,447.52/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $1,889.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DVAX + O for your $10,000?

DVAX: 50%O: 50%
100% O50/50100% DVAX
Portfolio after 10yr
$40.5K
Annual income
$3,991.09/yr
Blended yield
9.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

DVAX
Analyst Ratings
9
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$27.00
+74.2% upside vs current
Range: $20.00 — $32.00
Altman Z
2.4
Piotroski
6/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DVAX buys
0
O buys
0
No recent congressional trades found for DVAX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDVAXO
Forward yield12.90% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$46.8K ✓$34.2K
Annual income after 10y$2,879.44$5,102.74 ✓
Total dividends collected$20.6K$20.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$27.00$64.00 ✓

Year-by-year: DVAX vs O ($10,000, DRIP)

YearDVAX PortfolioDVAX Income/yrO PortfolioO Income/yrGap
1← crossover$11,990$1,290.32$10,818$608.16+$1.2K → DVAX
2$14,276$1,445.92$11,787$741.68+$2.5K → DVAX
3$16,884$1,608.88$12,946$911.00+$3.9K → DVAX
4$19,844$1,778.34$14,345$1,127.94+$5.5K → DVAX
5$23,186$1,953.40$16,056$1,409.05+$7.1K → DVAX
6$26,943$2,133.11$18,171$1,777.83+$8.8K → DVAX
7$31,145$2,316.51$20,820$2,268.21+$10.3K → DVAX
8$35,828$2,502.66$24,188$2,929.90+$11.6K → DVAX
9$41,026$2,690.60$28,533$3,837.11+$12.5K → DVAX
10$46,778$2,879.44$34,235$5,102.74+$12.5K → DVAX

DVAX vs O: Complete Analysis 2026

DVAX — Stock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Full DVAX Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this DVAX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DVAX vs SCHDDVAX vs JEPIDVAX vs KODVAX vs MAINDVAX vs STAGDVAX vs ADCDVAX vs NNNDVAX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.